- Home
- PERI vs URGN Comparison
PERI vs URGN Comparison
Compare PERI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERI
- URGN
- Stock Information
- Founded
- PERI 1999
- URGN 2004
- Country
- PERI Israel
- URGN United States
- Employees
- PERI N/A
- URGN N/A
- Industry
- PERI EDP Services
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- PERI Technology
- URGN Health Care
- Exchange
- PERI Nasdaq
- URGN Nasdaq
- Market Cap
- PERI 395.5M
- URGN 465.9M
- IPO Year
- PERI 2006
- URGN 2017
- Fundamental
- Price
- PERI $8.52
- URGN $10.08
- Analyst Decision
- PERI Hold
- URGN Strong Buy
- Analyst Count
- PERI 5
- URGN 6
- Target Price
- PERI $10.33
- URGN $42.25
- AVG Volume (30 Days)
- PERI 468.0K
- URGN 308.1K
- Earning Date
- PERI 02-19-2025
- URGN 03-13-2025
- Dividend Yield
- PERI N/A
- URGN N/A
- EPS Growth
- PERI N/A
- URGN N/A
- EPS
- PERI 0.25
- URGN N/A
- Revenue
- PERI $498,286,000.00
- URGN $89,363,000.00
- Revenue This Year
- PERI N/A
- URGN $12.17
- Revenue Next Year
- PERI N/A
- URGN $44.23
- P/E Ratio
- PERI $34.08
- URGN N/A
- Revenue Growth
- PERI N/A
- URGN 15.64
- 52 Week Low
- PERI $7.47
- URGN $9.78
- 52 Week High
- PERI $23.74
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- PERI 38.17
- URGN 40.55
- Support Level
- PERI $8.27
- URGN $9.86
- Resistance Level
- PERI $10.07
- URGN $11.87
- Average True Range (ATR)
- PERI 0.35
- URGN 0.50
- MACD
- PERI -0.13
- URGN -0.04
- Stochastic Oscillator
- PERI 13.89
- URGN 10.95
About PERI Perion Network Ltd.
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.